Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17275466 | 0.89 | SIRT2 (0.39) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL17275465 | 0.89 | SIRT2 (0.39) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL17275443 | 0.85 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL8524073 | 0.84 | SIRT2 (0.36) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL1040045 | 0.83 | CYP11B1 (0.41) | SIRT2CYP11B1CYP11B2ENPP2ALDH1A1 | |
| SCHEMBL28616157 | 0.83 | SIRT2 (0.38) | SIRT2CYP11B1CYP11B2NMBRCYP1A2 | |
| SCHEMBL28616160 | 0.83 | SIRT2 (0.38) | SIRT2CYP11B1CYP11B2NMBRCYP1A2 | |
| SCHEMBL670904 | 0.83 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2ALDH1A1 | |
| SCHEMBL5682164 | 0.83 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2CYP1A2 | |
| SCHEMBL4030251 | 0.82 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344777-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-7629472-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-08 | — | — | US | disclosed |
| EP-1222174-B1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA PHARMACEUTICAL (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20070276143-A1 | Method for producing optically active compound | YAMANO TORU | 2007-11-29 | — | — | US | disclosed |
| EP-1489070-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7247732-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060229457-A1 | Method for producing optically active compound | YAMANO TORU | 2006-10-12 | — | — | US | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1227086-B1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1489070-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6649643-B1 | Antitumor, anticarcinogenic, and antimetastasis agents; benign prostatic hyperplasia, alopecia, endometriosis, uterine myoma, hirsutism, virilism, precocious puberty, mastopathy, and polycystic overay syndrome treatment | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276143-A1 | Method for producing optically active compound | CYP8B1, HRH3, HRH1 | SIRT2 1128/4885CYP11B1 24/4885CYP11B2 43/4885 |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | SIRT2 2362/4885CYP11B1 9/4885CYP11B2 19/4885 |
| US-20060229457-A1 | Method for producing optically active compound | CYP8B1, HSD11B1, HSD17B7 | SIRT2 1117/4885CYP11B1 16/4885CYP11B2 34/4885 |
| US-20050107433-A1 | Process for production of optically active compounds | CYP8B1, HSD11B1, CYP51A1 | SIRT2 1689/4885CYP11B1 9/4885CYP11B2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.